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Expression of alternatively spliced mRNA variants at specific stages of development or in specific cells and tissues contributes to the
functional diversity of the human genome. Aberrations in alternative splicing were found as a cause or a contributing factor to the development,
progression, or maintenance of numerous diseases. The use of antisense oligonucleotides (ON) to modify aberrant expression patterns of
alternatively spliced mRNAs is a novel means of potentially controlling such diseases. Oligonucleotides can be designed to repair genetic
mutations, to modify genomic sequences in order to compensate for gene deletions, or to modify RNA processing in order to improve the effects
of the underlying gene mutation. Steric block ON approach have proven to be effective in experimental model for various diseases. Here, we
describe our experience in investigating two strategies for ON delivery: ON conjugation with basic peptides and lipid-based particulate system
(lipoplex). Basic peptides or Cell Penetrating Peptides (CPP) such as the TAT-derived peptide appear to circumvent many problems associated
with ON and drug delivery. This strategy may represent the next paradigm in our ability to modulate cell function and offers a unique avenue for
the treatment of disease. Lipoplexes result from the intimate interaction of ON with cationic lipids leading to ON carrying particles able to be
taken up by cells and to release ON in the cytoplasm. We have used as an experimental model the correction of a splicing alteration of the mutated
h-globin intron causing thalassemia. Data on cell penetration and efficacy of correction of specific steric block ON delivered either by basic
peptides or lipoplex are described. A comparison of the properties of both delivery systems is made respective to the use of this new class of
therapeutic molecules.
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modulation and for aberrant splicing correction
Conservative estimates suggest that over 75% of all pre-
mRNAs are spliced to yield alternative variants, the translated
products of which may have very different functions (review in
[1]). How the cell decides which alternative splice site to utilize
is not fully understood. However, it is generally believed that
splice site selection is controlled by the binding of trans-acting
protein factors to cis-acting sequences within pre mRNA
during spliceosome assembly. Aberrant splicing can result in
deleterious consequences for the organism. In fact, approxi-
mately 15% of all mutations that cause genetic diseases result
in defective splicing of pre-mRNA. For example, aberrant pre-
mRNA splicing occurs in genetic diseases such as B-
thalassemia, cystic fibrosis, neurofibromatosis type 1, ataxia-
telangiectasia, and congenital lipoid adrenal hyperplasia,
Alzheimer disease, myotonic dystrophy, and several cancers
[2].
The potential of sequence-specific recognition between
complementary nucleic acid sequences (Watson–Crick base
pairing) to control gene expression was first exploited over two
decades ago and has since been used in basic (e.g., as a tool to
assess gene function) and applied (e.g., to downregulate the
expression of genes causing human diseases) research. The
paradigm of the antisense strategy relies upon the hybridization
of a small single-stranded DNA fragment to a complementary
mRNA (or viral genomic RNA) target sequence, leading to the
inactivation of the latter by steric blockade or by RNase H
activation. Antisense approaches have been widely applied for
target validation or therapeutic purposes, and approximately 25
phase II/III clinical trials using these approaches are now in
progress (review in [3]).Catalytic RNA (ribozymes) and DNA
(DNAzymes) are also being considered as tools for the specific
degradation of an RNA target [4]. More recently, small
interfering RNAs (siRNAs) have shown great potential to
specifically trigger the destruction of an RNA target (review in
[5]). Finally, synthetic DNA or RNA fragments can be used to
compete for DNA- (transcription factors) or RNA-binding
proteins, respectively, in the decoy approach [6]. New and
increased attention has recently focused on antisense com-
pounds as a tool for correcting mutation leading to splicing
alteration [2].
To control pre-mRNA splicing patterns, antisense ON must
hybridize with specific splice sites and block spliceosome
assembly at the targeted splice site. This, because of the
flexibility of splicing machinery, does not result in total
inhibition of splicing, but in a shift of the spliceosome to
another splice site. As a consequence, an alternative splicing
pattern is established or a normally used alternative splice site
is used with increased efficiency. It has been shown in this and
other laboratories that antisense ON modify the splicingpatterns of pre-mRNAs that harbor aberrant splice sites or
aberrant sequence elements involved in splicing [2]. For
example, antisense ON have been used to restore correct pre-
mRNA splicing patterns of h-globin in h-thalassemia and
cystic fibrosis transmembrane receptor (CFTR) in cystic
fibrosis [2]. Antisense ON have also been used to induce an
alternative splicing pattern in a dystrophin pre-mRNA in
Duchenne’s muscular dystrophy and to affect the level of
expression of Bcl-x splice variants in cancer cells (reviewed in
[7]).
It therefore seems that manipulating the splicing pattern of
pre-mRNAs can be effective as a means to control a variety of
diseases.
2. Requirements for efficient splicing correction by
steric-block oligonucleotides
Implementation of antisense strategies has faced a number
of problems (some unforeseen) such as nuclease sensitivity,
target accessibility, target affinity, toxicity and delivery.
Numerous ON analogs have been designed in order to improve
target affinity and metabolic stability in a biological environ-
ment. Another frequently encountered drawback is the diffi-
culty of distinguishing an authentic antisense effect from non-
specific or toxic effects [8]. Steric block antisense for splicing
correction and siRNA are new classes of ON with higher
specificity, stability and consequently with higher potential
compared with the conventional antisense molecules.
As described in Section 1, splicing correction by the
hybridization of steric-block ON analogues (also called
splicing-switching ON) to cryptic splice sites has been
convincingly documented in several cases. Basic requirements
and problems experienced with all nucleic acids-based strate-
gies hold through in this case and will not been reviewed here.
To be effective the correcting ON should hybridize the pre-
mRNA in a sequence-specific fashion without activating a
nuclease. The use of phosphorothioate ON derivatives (whose
binding to complementary RNA recruits RNase H) or of
siRNA (which trigger the degradation of the target RNA
through a RISC complex-associated nuclease) is therefore
precluded. RNase H-incompetent ON analogues as charged
2VOalkyl ON derivatives, or neutral PMO (Phosphorodiamidate
Morpholino Oligonucleotides) and PNA (Peptide Nucleic
Acids) analogues have therefore been used in this aim [3].
These analogues have favourable pharmacologic properties in
terms of nuclease resistance and affinity for the targeted RNA
sequence. High affinity is particularly important since RNaseH
incompetent ON analogues will at best act in stoichiometric
amounts. Interestingly, RNaseH incompetent ON might be
acting more specifically than RNaseH activators. Indeed
RNaseH activation by antisense ON hybridized on a few
consecutive positions only to the target RNA sequence has
Fig. 1. Splicing correction assay: HeLa pLuc 705 cells were stably transfected
with a construction in which the coding sequence of the luciferase gene is
interrupted by a mutated intron 2 of the human h-globin gene. This mutation
creates a 5V splice site and activates a 3V splice site, leading to the production of an
aberrant non-functional protein (X). Masking of the 5V splice site by an RNase H-
incompetent antisense ON705 restores the production of functional luciferase
mRNA and protein [2]. Adapted from Kang et al. [50].
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same lines unmethylated DNA stretches and phosphorothioate
ON derivatives bind to Toll-like receptors on denditic cells
thereby triggering inflammatory responses in vivo. This has
not been reported to our knowledge for PMO and PNA
analogues.
Since pre-mRNA maturation takes place in nuclei, the
correcting ON should be delivered in this cellular compart-
ment. ON delivery is achievable in cell culture experiments
with the physical (scrape loading, electroporation or microin-
jection) or chemical (formation of complex to commercial
cationic lipids or to polyethylene-imine (PEI)) transfection
agents, which are commonly used for plasmid DNA delivery
(reviewed in [9,10]). Unfortunately, uncharged ON analogues
such as PMO or PNA cannot be transfected with cationic lipids
or PEI, and unassisted cellular uptake is very poor. Moreover,
most commercial cationic lipids formulations are not adapted to
systemic in vivo administration [9,11]. New lipoplex formula-
tions [12–14] and peptide-based delivery vehicles (reviewed in
[15,16]) with promising properties have been described by our
group as detailed in Section 4.
An alternative potential strategy for splicing correction
could capitalize on the fact that cis-elements governing
alternative splicing often work at a suboptimal level and
strictly require recognition by enhancer SR proteins [17].
Downregulation of these trans-acting elements can therefore be
envisaged by an siRNA strategy [9]. Again, however, the
implementation of in vivo siRNA strategies requires adequate
siRNA modification (to improve metabolic stability) and more
importantly suitable delivery vectors.
3. Present status with the delivery of steric block
oligonucleotides
Several approaches were explored in the way in develop-
ing steric block ON for correction of splice alterations. In
order to demonstrate the proof of principle of this strategy
various mechanical methods were used (i) Concentrating
PMO (45 AM) with cells by repetitive passages through
syringe with a 25-gauge needle [18]; (ii), electroporation with
2V-O-methoxyethyl modified ON [19]; (iii), or percutaneous
coronary intervention with PMO [20]. Interestingly, PMO
delivered by streptolysin O permeabilization (at 20 AM in
serum-free medium) induced missplicing of c-myc mRNA
[21].
Polymers forming polyplexes with nucleic acids were used
in a few studies. PANAM dendrimers are of interest as they
form stable particles in the presence of serum. However,
micromolar concentrations were needed and the heterogeneity
of particle size will probably preclude systemic injection. The
use of triblock copolymer F127 for the intramuscular admin-
istration of 2V-O-methyl phosphorothioate antisense ON was
described to efficiently restore dystrophic expression in skeletal
muscles [22]. Recently, antisense ON have also been used to
restore the disrupted reading frame of dystrophin mRNAs in
Duchenne muscular dystrophy (DMD). DMD patients suffer
from severe muscle degeneration due to frame-disruptingmutations in the DMD gene that prematurely abort the
synthesis of the dystrophin protein [22]. ON-induced restora-
tion of the DMD reading frame is based on inducing the
skipping of specific exons. This was successfully applied in
cultured muscle cells from DMD patients and in the mdx
mouse model [22,23]. High exon skipping levels of up to 90%
were achieved, allowing the synthesis of significant levels of
dystrophins in over 75% of treated cells. Stable long term
expression of antisense ON via AAV administration into
skeletal muscle generated sustained therapeutic levels of
rescued dystrophin in entire group of muscles [24].
Conjugation with basic peptides was reported to improve
significantly the activity of steric block ON. Sazani et al. [25]
reported that PNA-4K oligomers (PNA carrying 4 lysine
residues) lead to in vitro (30–300 nM) or in vivo (daily i.p.
injection of 50 mg/kg in mice) steric block activity in the h-
globin Kole’s assay (Fig. 1). Abes et al. (in press and section 5)
demonstrated that the same PNA-4K was able (at submicro-
molar concentration) to restore correct h-globin intron splicing
in cultured cells but only when endosome-disrupting agents
were concurrently administered to cells. Moulton et al. [26]
investigated the ability of the Tat-derived CPP (pTat) to deliver
PMO into cultured cells. pTAT-PMO conjugate targeted to c-
myc mRNA downregulated c-myc reporter gene expression
with an IC50 of 25 AM. pTat appeared to be 7, 5, and 6 times
more efficient than three other CPP: pep-1, KFC, and NLS,
respectively [26].
Lipoplexes are to date the most employed tools to deliver
steric block ON. PMO delivered with the Lipofectin system
(Invitrogen Corp, Carlsbad, CA) were active at 100 nM in
cultured muscle cells and in vivo following intramuscular
administration of 50 Ag/kg in mdx mice [27]. Likewise,
splicing correction was achieved with 2V-O-methyl phosphor-
othioate ON and PMO delivered with the Lipofectamine
reagent (Invitrogen Corp., Carlsbad, CA) [18,25]. Those
commercially available delivery systems suffer of instability;
and serum-free medium is therefore recommended for trans-
fection. In vivo use of lipoplex in delivering steric block ON is,
consequently, poorly documented in the literature.
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Delivery within the appropriate intracellular compartments
remains a limiting factor for all nucleic acids-based
strategies used for the control of gene expression. Endocy-
tosis of free material into most cell types is an inefficient
process. Instability in a biological environment and poor
cellular uptake are limiting factors in the therapeutic
development of ON [28–30]. Appropriate delivery or
chemical modification of synthetic ON should, in principle,
improve their pharmacological properties through protection
from nucleases and by easing their passage through
biological barriers. Basically, three strategies are under
examination: (i) ON chemical modification, (ii) association
with a particulate delivery system, and (iii) conjugation with a
hetero-component. We describe below our experience regard-
ing the use of lipoplex-formulated ON and ON-conjugated
CPPs.
4.1. ON delivery via Tat peptide conjugation
Much excitement has been generated by the serendipitous
discovery by Prochiantz et al. [31] of the transmembrane
passage of the Drosophila (Antp) protein. Membrane translo-
cation and nuclear delivery has rapidly been assigned to a
relatively small (16-mer) basic amino acid-rich peptide
belonging to the DNA binding domain of Antp transcription
factor [31]. Along the same lines, and to the surprise of
virologists, an HIV-1 promoter could be transactivated by
incubation of intact cells with the purified Tat protein. An 11-
amino acid arginine-rich (GRKKRRQRRRC) peptide belong-
ing to the RNA binding domain of Tat has been defined by our
group and shown to be able to cross membranes [32]. Other
peptides or peptide-mimics have since been engineered for
drug delivery under the generic name of cell penetrating
peptides, or CPP. CPPs can be internalized in most cell types
and, more importantly, allow the cellular delivery of conju-
gated (or fused) biomolecules. A wide range of biomolecules
such as antigenic peptides, PNA, antisense ON, full-length
proteins, or even nanoparticles and liposomes have been
delivered this way [15,16]. Most peptide- and nucleic acid-
based drugs are poorly taken up in cells, and this is considered
a major limitation in their development as therapeutic agents
[32]. Conjugation of therapeutic agents to CPPs could thus
become a strategy of choice to improve their pharmacological
properties.
Langel et al. have provided the key initial data in the field
through conjugation of a galanin receptor-specific PNA to
transportan, a synthetic CPP [33]. The PNA-transportan
complex was delivered within intact neurons in culture and
was shown to downregulate the galanin receptor. Most
impressively, these same conjugates inhibited galanin receptor
expression after injection into mice. PNA delivery into neurons
within the brain implied that transportan–PNA conjugates
crossed the blood–brain barrier. This may have wide applica-
tions in neurobiology and in the treatment of central nervous
system-associated diseases [34].Similarly, a PS-antisense ON conjugated via a disulfide
bridge to Antp or Tat peptide has been used to downregulate
the expression of the MDR1 gene in cultured cells [15,35].
Although biological responses could be achieved at sub-
micromolar concentrations, cationic lipid-mediated delivery is
more efficient than the CPP-driven delivery in this assay.
Interestingly, the biological response was enhanced in cells
cultured in serum-rich medium in contrast to data obtained with
cationic lipid-mediated delivery. The low toxicity of CPPs and
their effectiveness in the presence of serum appear advanta-
geous for in vivo applications [16]. CPP were initially thought
to be internalized by energy-independent translocation through
the plasma membrane. We re-evaluated the mechanisms of
cellular uptake of TAT 48–60 and (Arg)9. Fluorescence
microscopy on live unfixed cells shows characteristic endoso-
mal distribution of peptides [36]. Peptide uptake is inhibited by
incubation at low temperature, by cellular ATP pool depletion
and by inhibitors of endocytosis [37]. Similar data were
obtained for Tat-conjugated PNA. These data are consistent
with the involvement of endocytosis in the cellular internali-
zation of CPP and their conjugates to PNA. Although much
remains to be done to delineate the CPP mechanism of uptake,
entrapment within endocytic vesicles may be limiting in this
strategy as indicated in Section 5.
Numerous methods have been reported for the synthesis of
CPP–ON conjugates. The few previously claimed successes
for cell delivery and biological activity of CPP–ON conjugates
have all used disulfide linkages between oligonucleotide and
peptide moieties [38]. We have defined a simplified method for
oligonucleotide activation leading to high yield synthesis of
peptide-ON chimera through a disulfide bridge [39].
An example of the intracellular trafficking of ON when
delivered with Tat conjugation is given in Fig. 2. We carried
out fluorescence microscopy analysis of endothelial HUVEC
and HeLa live cells treated with Tat–PNA. Alexa labeled
Tat–PNA conjugates (green fluorescence) rapidly enter cells
and essentially distribute in a punctuate pattern in the
cytoplasm (Fig. 2A). This localization corresponds to
endosomic vesicles as attested by co-localization with the
transferrin-alexa 546 (red fluorescence, Fig. 2B) endosomes
marker (yellow staining) (Fig. 2C). This distribution pattern is
not modified and fades upon a longer incubation period.
Intracellular fluorescence is not detected when free PNA is
used suggesting no (or poor) PNA cell uptake (data not
showed). However, there is no detectable release of PNA into
the cytosol, and consequently, no apparent distribution in the
nuclear compartment.
While investigating the role of arginine rich motifs in gene
delivery, it was demonstrated that oligomers of TAT CPP
compacted plasmid DNA to nanometric particles and stabi-
lized DNA toward nuclease degradation. Such TAT peptide
complexes were superior to PEI in terms of transfection
efficiency. In addition, gene transfer was enhanced due to
TAT nuclear localization sequence. TAT CPP interacted with
plasmid DNA electrostatically and the resulting complexes
were transferred to mammalian cells by an endocytosis-
mediated pathway [37,40,41].
Fig. 2. Fluorescence microscopy images in unfixed HUVEC (panels A–C) or HeLa pLuc 705 (panels D–F) cells. HUVEC cells incubated with 1 AM of Tat–PNA
(Alexa 488) (green color) for 30 min at 37 -C (panel A) and thereafter with 25 Ag/ml transferrine-alexa 546 (red fluorescence) (panel B) for 5 min. HeLa pLuc 705
cells incubated with 2 AM Fam tagged (green fluorescence (Lys)8–PNA705–Lys (panel D) for 4 h and thereafter with Alexa 546-tagged (red fluorescence)
transferrin (panel E) for 5 min. Nuclei were stained with Hoechst (blue fluorescence) for 5 min. Co-localization was revealed in panels C and F (yellow staining).
TAT–PNA conjugates were synthetized and characterized as described in [36].
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As previously stated, the association of antisense ONs (and
more recently of siRNA) to several commercially available
cationic lipid formulations is, for the time being, the most
reliable and easy strategy to transfect these ON into cells in vitro,
despite occasional side effects and resistance of several primary
cells. Careful optimization should however be completed for
each application as the efficacy (and importantly the toxicity) of
different formulations vary depending on the cell type and ON
analog utilized. Complex formation of DNAwith cationic lipids
[42] leads to the respective condensation of both entities by
electrostatic interactions. As a consequence, control of the
thermodynamic parameters of complex formation is crucial to
obtain homogeneous and reproducible particles. In addition,
lipoplexes global net charge is cationic leading to unstability in
the presence of serum and toxicity [9–11]. Positively charged
lipoplexes indeed bind to anionic serum proteins. This leads to
inactivation and toxicity (for instance to red blood cells) and first
pass effect in lung [10]. This is the reason whymost successful in
vivo data were obtained with using local administration of
nucleic acids. Pharmacologically efficient synthetic vectors are
therefore still lacking for most in vivo applications and clinical
developments, especially for systemic administration.
Our initial goal was to obtain pharmaceutically suita-
ble vectors regarding stability and reproducibility. We havedesigned and developed an efficient lipidic vector termed as
DLS [11,12]. We have set and defined the optimal thermody-
namic conditions either for the lipids or the nucleic acid
presentation. Lipids were presented in a liposome forming
specific Small Unilamellar Vesicles (SUV) composed of a
poly-cationic lipid (DOGS) and a neutral lipid (DOPE)
[11–13]. DLS SUVs interacted with DNA to form highly stable
(up to 3 months at 4 -C) and homogeneous (120 nmT20%;
polydispersity=20) complex particles [11,43]. Uptake and
intracellular distribution were studied in various cell culture
models with various ON types (modified or unmodified)
[29,43,44]. Our observations suggested that complete DNA
release from the endocytic vesicles can be achieved and support
the notion of the complete or partial release of the DNA from
the lipidic carrier [28,29,44].
We have evaluated the specificity and activity of antisense
ON against HIV infection with regard to dose–response range,
number and choice of experimental controls, ON backbone
modifications, type of cell infection, length of assays and
delivery approach by the DLS lipoplex system [8]. The highest
potency (IC50 level at picomolar range) was observed in a
short-term chronic infection model with DLS-delivered ON
where the DLS delivery improved the ON activity up to 106
times compared to free chemically modified ONs [8,43].
Likewise, we recently reported the use of antisense ON
directed against VEGF RNA for treating AIDS Kaposi’s
A.R. Thierry et al. / Biochimica et Biophysica Acta 1758 (2006) 364–374 369Sarcoma in vitro and in vivo setting [29]. Up to 93% of sequence
specific inhibition of tumorigenesis was observed with using a
clonogenic assay. Significant activity (39% inhibition) was
observed at nanomolar range dose (10 nM). Daily intra-tumoral
administration of VEGF-ON conduces to a marked change in
tumor growth, in cell proliferation and in the number of mitotic
figures as observed in thin tissue sections [29].
Biophysical examination of Neutraplex and DLS revealed a
specific ultrastructure consisting of liquid crystals composed of
lamellar or hexagonal phases [46]. This specific ultrastructure
may be responsible for the high reproducibility and homoge-
neity of these lipoplex particles. Remarkably, the concentric
and lamellar structure with different packing regimes was also
observed with linear double-stranded DNA, single-stranded
DNA and circular double-stranded plasmid DNA [46].
Systemic administration of plasmid DNA delivered with the
DLS system led to widespread and long-lasting reporter gene
expression [12]. We further demonstrated increased DNA
plasma half-life and efficient uptake in blood cells following
intravenous administration in mice [13]. The DLS system was
applied in various in vivo models for therapeutic gene transfer
such as human MDR1 expression in mouse bone marrow
progenitor cells [47], and glucocerobrosidase gene transfer [48].
Despite their very low positive charge ratio (1.7 compared
to 4.0–8.0 for commercially available formulations), DLS still
suffer from drawbacks inherent to lipoplex vectors for in vivo
application, especially when considering systemic administra-
tion of nucleic acids [10 11]. Whereas DLS mediated gene
transfer is not inhibited by serum [11,13,47,48], DLS-ON
activity is slightly inhibited in serum containing medium.
However, high level ON activity was observed at concentra-
tions in serum-containing medium to which no effect could be
detected with commercially available cationic lipids such as
Lipofectamine.
We have therefore developed for the first time an anionic
lipoplex delivery system named Neutraplexi [14]. These
particles are composed of a poly-cationic lipid (DOGS), a
neutral lipid (DOPE), and an anionic phospholipid (cardiolipin)
that interacted with DNA [46]. The pharmacokinetics and
bioavailability following intravenous administration in
baboons of an ON delivered either in a free form, or using a
cationic or the Neutraplex carrier system were compared [14].
Whole body distributions and metabolism was monitored using
Positron Emission Tomography and an enzyme-based compet-
itive hybridization assay. Free phosphodiester ON showed
typical pharmacokinetics, e.g., high liver and kidney concen-
tration, rapid plasmatic degradation and elimination from the
body. The cationic vector slightly protected ON against
degradation and enhanced uptake by the reticulo-endothelial
system but not by other organs. In contrast, the anionic vector
dramatically enhanced the uptake in several organs, including
the lungs, spleen and brain, with a prolonged accumulation of
radioactivity in the brain. Using this vector, intact ON were
detected in the plasma for up to 2 h after injection, and the T1/
2h (ON half life) and distribution volume increased by 4- and
7- fold, respectively [14]. No evidence of toxicity was found
upon administration of 100 Ag/kg every week over a 4-weekperiod. The anionic vector thus improved significantly the
bioavailability and the pharmacokinetics profile, and appears as
a promising delivery system for in vivo administration of
therapeutic ON.
As delivery to cells is not enough to ensure ON activity, ON
bioavailability in cellular compartments was investigated
[29,44,45]. Our long experience in studying nucleic acids
intracellular distribution proved to us the need of observing
labeled ON solely in live cells as fixing agents modify integrity
of intracellular membranes and modify intracellular trafficking
[13,29,36,44]. An example of uptake in live cells with lipoplex
systems is presented in Fig. 3. Epifluorescence images of
unfixed HeLa ovarian cancer cells incubated with 2V-O-methyl
modified ON delivered with the DLS system are presented.
Following 2-h incubation FITC (green fluorescence) labeled
ON distribute nearly exclusively in small cytoplasmic vesicles
in the cytoplasm (Fig. 3A). This vesicular localization
corresponds to endosomes since Transferrin-alexa 546 (red
fluorescence) nearly completely co-localizes with ON (yellow
fluorescence) (Fig. 3B and C). Following 12-h incubation, the
green fluorescence mainly distribute in the nucleus whereas
punctuate Transferrin red fluorescence remains in cytoplasmic
vesicles (Fig. 3D and E). This suggests a rapid escape of ON
from the endosomes, release in the cytosol and apparent
complete diffusion of ON into the nucleus as previously
described [13,29,44]. It was shown that ON have a ‘‘natural
tropism’’ to the nucleus since ON microinjected in cytoplasm
rapidly localize in the nucleus [49]. Optimal nuclear penetra-
tion was observed after a 12-h incubation time period, the
overall fluorescence intensity being markingly decreased
following 24 h incubation (data not shown). Whereas free
ON poorly penetrate in cells and mainly distribute in endocytic
organelles [28,29], DLS lipoplexes thus facilitate ON delivery
in the nuclear compartment.
5. Basic peptides and lipoplexes for the delivery of splice
correcting oligonucleotides
The efficiency with which CPP and lipoplexes allow for the
delivery of splice correcting ON has been assessed in the
elegant model proceeded by Kole et al. [2]. In this assay, a
mutated intron carrying an aberrant splice site has been inserted
within a luciferase reporter gene, thus preventing the produc-
tion of a functional mRNA. The hybridization of a RNaseH
incompetent ON analogue to this cryptic splice site restores
correct splicing and consequently the production of luciferase
(Fig. 1). This assay is now considered as the most valuable to
assess in vitro or in vivo nuclear delivery of an antisense ON
since it provides a positive readout. In this assay, we use 18
mer 2V-O-methyl ON (ON705) or PNA (PNA705)as designed by
Kole and co-workers [50].
5.1. Use of DLS lipoplex for delivering steric block ON in
Kole’s model
Luciferase activity in DLS-Antisense sequence (DLS-
ON705) treated cells was 22- and 28-fold higher than that of
Fig. 3. Fluorescence microscopy images of live HeLa pLuc 705 cells. Cells were incubated with 200 nM FITC ON705 (green color) (panels A and D), using the DLS
delivery system, in optiMEM medium for 2 h (panels A–C) or 12 h (panels D–F) or with 25 Ag/ml transferrin-alexa 546 (red fluorescence) (panels B and C). Co-
localization was revealed in panels C and F (yellow staining). DLS lipoplexes were prepared as described in [43].
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cells, respectively (Fig. 4A). No detectable activity was
observed with free antisense ON (data not shown). Kinetic
study enabled us to determine an optimal treatment time between
12 and 24 h. Dose response experiments showed an optimal
sequence specific activity at 100 nM with no detectable toxicity
up to 300 nM. A statistically significant difference (Student’s
t-test,P0.05) between the DLS-ON705 and the DLS-ONsc was
observed at ON doses as low as 1 nM (Fig. 4B). Moreover, the
DLS-ON705 was approximately 2.5 times more effective than
lipofectamine-ON705 (LFA) in optiMEM medium (Fig. 4A).
High level luciferase expression was observed in cells incubated
with DLS-ON705 in serum-containing medium while no activity
was found in cells treated with Lipofectamine (LFA)-delivered
ON at a concentration of 100 nM (data not shown). The marked
increase of luciferase activity in cells incubated with a scrambled
control ON (ONsc) delivered with LFA compared with that ofuntreated cells illustrates toxic effect or metabolic changes
arising from the use of the LFA lipids. Correction of splicing
alterations in thalassemia transgenic mouse models will be
evaluated with these lipoplex formulations.
5.2. Use of basic peptides for delivering steric blocking ODN
in Kole’s model
As mentioned in section 3, the conjugation of a small
oligolysine tail to the C-terminus of an uncharged steric block
PNAwas able to mask a splice site and to re-orient pre-mRNA
maturation (PNA705). This elegant and simple strategy could
provide an alternative to lipoplexes or CPPs delivery.
As shown in Fig. 4, free PNA 705-Lys did not increase
luciferase activity in keeping with the inefficient cellular uptake
reported in previous studies [50,51]. Surprisingly however,
splicing correction by the (Lys)8–PNA705–Lys conjugate was
Fig. 4. Luciferase activity in pLuc705 HeLa cells transiently transfected during 24 h with antisense ON705 or scrambled ON (ONsc), using the DLS delivery system,
in optiMEM medium. (A) Comparison of transfection efficiency between the DLS delivery system and lipofectamine (LFA), at a concentration of 30 nM ON. (B)
Effect of ON doses in DLS. ON705 (black columns) and scrambled ON (shaded) are compared. The experiment corresponding to non-treated cells is showed (white
column). Values are means (TS.D.) of triplicate Luciferase determinations from three independent experiments. Bar between two columns represents multiplication
factor. The activity of luciferase was normalized in total cellular protein and is presented in relative luminescence units (RLU) per Ag of protein. Statistical
differences between RLU/Ag values from scrambled and antisense oligonucleotides treated cells were evaluated: *P0.05; ***P0.001. Luciferase expression was
monitored as described in [50].
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with lipoplex-delivered 2VOMet ON analogues. Likewise, a
(Lys)8–PNA705–Lys construct of appropriate sequence was
ineffective in a TAT/TAR transactivation inhibition assay in a
parallel study [60].
Since FACS analysis established that (Lys)8–PNA705–Lys
conjugates were internalized efficiently by an energy-depen-
dent mechanism, the low biological activity in the splicing
correction assay could result from sequestration in endocytic
compartments and/or from degradation by lysosomal enzymes
(although the modified backbone of PNAs renders them rather
resistant to proteases and nucleases).
Accordingly, fluorescence microscopy analysis of live
unfixed HeLa pLuc 705 cells incubated with (Lys)8–PNA705–
Lys (Fam) revealed a characteristic cytoplasmic punctate
distribution. Little if any (Lys)8–PNA705–Lys (Fam) staining
could be detected in cell nuclei (Fig. 2D–F).
The most commonly used pharmacological agent to
promote increased delivery of drugs sequestered in endocytic
compartments is chloroquine, a lysosomotropic amine acting as
a buffering agent and as a consequence preventing endosomeacidification [51]. It has, in particular, been used to improve the
functional delivery of plasmid DNA by non-viral vectors
[53,54]. Cells were co-incubated with the (Lys)8–PNA705–Lys
conjugate and 100 AM chloroquine for 4 h, a protocol in which
no significant chloroquine-induced cytotoxicity was observed
(as monitored by the absence of propidium iodide labeling). As
shown in Fig. 5A, chloroquine co-treatment very significantly
increased splicing correction by (Lys)8–PNA705–Lys conju-
gates and correction reached comparable levels observed with
2VOMet ON delivered with DLS lipoplexes. Chloroquine did
not increase the efficiency of free PNA as expected since
neutral PNAs are very poorly internalized [55]. The sequence-
specificity of splicing correction was verified with a scrambled
version of the (Lys)8–PNA705–Lys construct (Fig. 5). Rela-
tively high concentrations (500 nM or more) of the conjugate
were nevertheless required to achieve a significant increase in
luciferase activity even in the presence of chloroquine.
Although it is difficult to compare steric block agents which
differ in their chemistry, 2VOMet ON were active in the low
nanomolar range when delivered with DLS lipoplexes (Fig. 4).
On the other hand, correction by (Lys)8–PNA705–Lys con-
Fig. 5. Effect of chloroquine on splicing correction by (Lys)8–PNA705–Lys conjugate. (A) HeLa pLuc 705 were incubated in the absence of correcting ON (1), in
the presence of 30 nM ON705 (2) and ONsc(3) delivered with DLS lipoplex, 1 AM free splice correcting PNA705 without (4) or with (5) chloroquine (100 AM), or in
the presence of 1 AM (Lys)8–PNA705–Lys without (6) or with (7) chloroquine (100 AM). Data are expressed in RLU/Ag protein. Experiments have been made in
triplicate and averaged. Error bars are indicated. (B) Specificity of splicing correction. Cells were incubated in presence of 1 AM (Lys)8–PNA705 scrambled-Lys
without (2) or with (3) chloroquine (100 AM), or in presence of (Lys)8–PNA705–Lys 1 AM without (4) or with (5) chloroquine (100 AM). Control in with no
addition (1). Data are expressed as in panel A.
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out in serum-containing culture medium while lipoplex
delivery was partially inhibited by serum proteins in keeping
with previous studies with cationic lipid formulations [30].
Likewise, cell incubation in the presence of high sucrose
concentration is known to promote endosome swelling and to
increase release of endosome-sequestered material [52]. Co-
incubation with 0.5 M sucrose largely increased luciferase
expression in (Lys)8–PNA705–Lys treated cells but not in
cells treated with the scrambled version of the conjugate (Abes
et al, in press). These experiments clearly establish that
sucrose or chloroquine treatment very significantly increases
splicing correction by (Lys)8–PNA705–Lys in a sequence-
specific manner, in line with the well-established endosome-
destabilizing activity of these two drugs. Likewise, endosome
destabilization by lysosomotropic agents or by fusogenic
peptides improved the functional delivery of Cre recombi-
nase–TAT fusion proteins [56,57]. Moreover, chloroquine
treatment significantly enhanced the inhibition of HIV-1 Tat-
dependent trans-activation by PNA 16-mer either, stably
polyether linked, or disulfide linked to several cell-penetrating
peptides [60].
6. Future directions
In optimal experimental conditions, basic peptides or
lipoplexes efficiently deliver splice correcting ON in nuclei.The apparent instability of most lipoplex formulations in serum
containing medium appears as a drawback for in vivo applica-
tions. The development of negatively charged [9,14] or sterically
stabilized lipoplexes will be required for systemic administra-
tion. However, cationic lipoplexes could potentially be useful
when local administration is appropriate to achieve disease
treatment. Second, more has to be done to reduce the toxicity of
cationic constituents for red blood cells, for instance.
Basic peptides or CPP are advantageous vector system
compared to particulate systems regarding synthesis, cost, and
pharmaceutical development, in particular for quality control
and scalable process production. In contrast to lipoplexes, basic
peptides make possible delivery of uncharged PNA or PMO.
One of the basic peptides drawback appears to be the need of
the concurrent treatment of endosomes releasing agents in
order to concentrate ON in the nucleus where splice correction
occurs. Although lysosomotropic agents such as chloroquine
are pharmacologically well known, the presence of a third
constituent, in addition to the steric block ON and the basic
peptide heteroconjugate, might decrease the tolerated clinical
doses. Multifunctional basic peptides containing for instance an
hydrophobic part or a nuclear localization signal [58] might be
a solution to improve intracellular trafficking and their efficacy
[59]. Basic peptides hetero-conjugation for ON delivery seems
as well to partially protect ON towards degradation and activity
requires higher doses compared to lipoplex (10- to 100-fold).
All those parameters should be taken into consideration in
A.R. Thierry et al. / Biochimica et Biophysica Acta 1758 (2006) 364–374 373order to evaluate their use in therapy. Despite severely
complicating formulation process, combining both approaches
might improve delivery parameters, and this is under investi-
gation in our laboratory.
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